Related Experiment Videos
Antitumor activity of basic fibroblast growth factor-saporin mitotoxin in vitro and in vivo
J G Beitz1, P Davol, J W Clark
1Roger Williams Cancer Center, Brown University, Providence, Rhode Island 02908.
Abstract:
Many cancer cell lines express basic fibroblast growth factor (FGF) receptors, making them potential targets for the delivery of FGF-based cytotoxic compounds. To this end, we have investigated the antitumor activity of a novel mitotoxin, Fibroblast Growth Factor-saporin (FGF-SAP), a conjugate of FGF and the ribosome-inactivating protein, saporin. In vitro, FGF-SAP is cytotoxic for human melanoma, teratocarcinoma, and neuroblastoma cells expressing FGF-receptors. Mice treated with FGF-SAP i.v., on a variety of schedules, showed dramatic tumor growth inhibition with minimal toxicity. Thus, FGF-SAP appears to be a well-tolerated and potent antitumor agent. The potential of FGF-targeted cytotoxicity is discussed.
Insights
A new compound, Fibroblast Growth Factor-saporin (FGF-SAP), shows potent antitumor activity by targeting cancer cells expressing FGF receptors. This novel agent demonstrated significant tumor growth inhibition with minimal toxicity in preclinical studies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Cancer cell lines often express fibroblast growth factor (FGF) receptors.
- These receptors present a target for developing FGF-based cytotoxic compounds.
- Targeted drug delivery aims to enhance efficacy and reduce systemic toxicity.
Purpose of the Study:
- To investigate the antitumor activity of a novel conjugate, Fibroblast Growth Factor-saporin (FGF-SAP).
- FGF-SAP combines FGF with the ribosome-inactivating protein saporin for targeted cancer cell killing.
- To evaluate the efficacy and toxicity of FGF-SAP in preclinical models.
Main Methods:
- Synthesis of FGF-SAP, a conjugate of FGF and saporin.
- In vitro cytotoxicity assays on human cancer cell lines (melanoma, teratocarcinoma, neuroblastoma) expressing FGF receptors.
- In vivo studies in mice to assess tumor growth inhibition and toxicity following intravenous administration of FGF-SAP.
Main Results:
- FGF-SAP demonstrated in vitro cytotoxicity against human melanoma, teratocarcinoma, and neuroblastoma cells.
- Intravenous administration of FGF-SAP in mice resulted in significant tumor growth inhibition.
- The treatment exhibited minimal toxicity in the animal models.
Conclusions:
- FGF-SAP is a potent and well-tolerated antitumor agent.
- The FGF-targeted cytotoxicity approach shows significant promise for cancer therapy.
- Further investigation into FGF-SAP's therapeutic potential is warranted.